Liquidia Corp (LQDA) Stock Price & Analysis
Liquidia Corp (LQDA) rose 0.17% to USD 64.01 as of June 10, 2026 at 05:11 UTC, according to Nexqual real-time market data.
LQDA last closed at USD 63.9; the session ranged USD 61.72–65.95 on volume of 1,623,883 shares. Market capitalization is $5.69B, with a 52-week range of USD 11.85–66.78 (NCM). Source: Nexqual, June 10, 2026 at 05:11 UTC.
Key Statistics (as of June 10, 2026 at 05:11 UTC)
| Price | USD 64.01 |
|---|---|
| Change | ▲ 0.17% (up) |
| Previous Close | USD 63.9 |
| Open | USD 64.41 |
| Day Range | USD 61.72 – 65.95 |
| 52-Week Range | USD 11.85 – 66.78 |
| Volume | 1,623,883 shares |
| Market Cap | $5.69B |
| Exchange | NCM |
Technical Analysis (LQDA)
Nexqual's technical model rates LQDA "STRONG BUY" based on 5 bullish and 0 bearish signals across 123 daily candles, as of June 10, 2026 at 05:11 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 69.85 (neutral) |
| vs SMA50 | Above (USD 46.89) |
| MACD | 4.27 (positive) |
Analyst Ratings (LQDA)
Wall Street analysts rate LQDA "Strong Buy" based on 8 analysts, with a mean price target of USD 66.13 (range USD 59–75), per Nexqual as of June 10, 2026 at 05:11 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 8 |
| Mean Target | USD 66.13 |
| High Target | USD 75 |
| Low Target | USD 59 |
| Buy / Hold / Sell | 8 / 0 / 0 |
Earnings (LQDA)
| Next Earnings Date | 2026-08-12 |
|---|---|
| EPS Estimate | USD 0.84 |
| Revenue Estimate | $170.98M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.52 vs est 0.41 ▲ beat |
| 2025-12-31 | USD 0.15 vs est 0.33 ▼ miss |
| 2025-09-30 | USD -0.04 vs est -0.35 ▲ beat |
| 2025-06-30 | USD -0.49 vs est -0.39 ▼ miss |
Source: Nexqual, June 10, 2026 at 05:11 UTC.
Financials & Fundamentals (LQDA)
| Total Revenue | $288.06M |
|---|---|
| Revenue Growth (YoY) | +4158.50% |
| Gross Margin | +91.81% |
| Operating Margin | +46.29% |
| Profit Margin | +7.74% |
| ROE | +28.18% |
| Debt / Equity | 170.22 |
| Current Ratio | 2.22 |
| Total Cash | $222.79M |
| Total Debt | $184.82M |
| Free Cash Flow | $9.58M |
Source: Nexqual, June 10, 2026 at 05:11 UTC.
Financial Health Score (LQDA)
Nexqual rates Liquidia Corp's overall financial health "Solid" across five dimensions, as of June 10, 2026 at 05:11 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Strong — Gross margin 92%, operating 46% |
| Balance Sheet | Weak — $223M cash vs $185M debt, net cash position |
| Cash Flow | Solid — FCF $10M, 6% margin |
| Efficiency | Strong — ROE 28%, ROA 9.1% |
Ownership (LQDA)
| Insider Ownership | +12.69% |
|---|---|
| Institutional Ownership | +70.12% |
| Shares Outstanding | 88.93M |
| Float | 62.62M |
| Short % of Float | +13.91% |
Source: Nexqual, June 10, 2026 at 05:11 UTC.
Leadership (LQDA)
Liquidia Corp is led by Roger A. Jeffs (age 63), CEO & Director, per Nexqual as of June 10, 2026 at 05:11 UTC.
| CEO & Director | Roger A. Jeffs (age 63) |
|---|---|
| COO & CFO | Michael Kaseta (age 49) |
| Senior Vice President of Marketing | Michael Post |
| Senior Vice President of Sales | Matt Snow |
Major Backers & Investors (LQDA)
Notable institutional backers of Liquidia Corp include Farallon Capital Management LLC, Caligan Partners, LP, Findell Capital Management LLC, according to Nexqual as of June 10, 2026 at 05:11 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Farallon Capital Management LLC | 9.73% |
| Caligan Partners, LP | 9.13% |
| Findell Capital Management LLC | 3.94% |
| Opaleye Management Inc. | 2.86% |
| Bank of America Corporation | 2.57% |
| MPM Bioimpact LLC | 1.58% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 8.51% |
| Vanguard Group | 6.86% |
| Geode Capital | 2.17% |
| State Street | 2.12% |
Source: Nexqual, June 10, 2026 at 05:11 UTC.
From Liquidia Corp's Latest SEC 10-K Filing (filed 2026-03-05)
Key Strengths & Strategy (as disclosed to the SEC)
- Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States.
- The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
- It also provides Remodulin, a treprostinil injection administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil which is in phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
- In addition, the company offers PRINT technology which allows to engineer and manufacture uniform drug particles with precise control over the size, three-dimensional geometric shape, and chemical composition of the particles.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CRNX | Crinetics Pharmaceuticals, Inc. | USD 34.97 | ▲ 6.23% |
| SRRK | Scholar Rock Holding Corporatio | USD 45.58 | ▲ 2.89% |
| MIRM | Mirum Pharmaceuticals, Inc. | USD 95.48 | ▲ 2.14% |
| VRCA | Verrica Pharmaceuticals Inc. | USD 6.12 | ▲ 1.32% |
| KNSA | Kiniksa Pharmaceuticals Interna | USD 48.7 | ▲ 0.58% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 05:11 UTC. This page is informational and not investment advice.